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MedtA preliminary analysis of late structural failures of the Navion stent
graft in the treatment of descending thoracic aortic aneurysms
Fabio Verzini, MD, PhD, FEBVS,a Enrico Cieri, MD, PhD,b Andrea Kahlberg, MD,c Yaron Sternbach, MD,d
Robin Heijmen, MD, PhD,e Kenneth Ouriel, MD,f Sam Robaina, MS,g and Ali Azizzadeh, MD, FACS,h Turin,
Perugia, and Milan, Italy; Albany and New York, NY; Nieuwegein, The Netherlands; and Santa Rosa and Los Angeles, CalifABSTRACT
Objective: Patients in the Valiant Evo U.S. and international clinical trials had positive short-term outcomes; however, late
structural failures, including type IIIb endoleaks have been recently discovered. Type IIIb endoleaks are serious adverse
events because the repressurization of the aneurysm sac increases the risk of rupture. The purpose of the present study
was to detail the imaging patterns associated with the structural failures with the aim of increasing awareness of failing
graft presentation, early recognition, and prompt treatment.
Methods: The Valiant Evo clinical trial was a prospective, single-arm investigation of a thoracic stent graft system. With
the recent late structural failures, sites were requested to submit all available imaging studies to date to allow the core
laboratory to assess for structural failures such as type IIIb endoleaks, stent ring fractures, and stent ring enlargement. Of
the 100 patients originally enrolled in the trial from 2016 to 2018, the core laboratory assessed the imaging studies
performed at $1 year for 83 patients.
Results: No structural failures of the graft were reported through 1 year of follow-up. At 1 to 4 years, graft structural failures
were detected in 11 patients with descending thoracic aortic aneurysms. Of the 11 patients, 5 had a type IIIb endoleak.
Four of the five had imaging findings showing stent fractures consistent with the location of the graft seam and one had
a type IIIb endoleak attributed to calcium erosion with no stent fracture or ring enlargement. Of the four patients with
stent fracture in line with the graft seam, three underwent a relining procedure that successfully excluded the type IIIb
endoleak. One of these three patients died 4 days later of suspected thoracic aortic rupture because the distal thoracic
endovascular aortic repair extension had been landed in a previously dissected and fragile section of the aorta. The
remaining six patients had had stent ring enlargement. One of the six patients had had persistent aneurysm expansion
from the time of implantation onward and had died of unknown causes. The remaining five patients have continued to
be monitored.
Conclusions: In thepresentpreliminaryanalysis, the imagingpatternsassociatedwithtype IIIbendoleaks, stent fractures, and
stent ring enlargement appear to be related to the loss of seam integrity or detachment of the stent rings from the surface of
the graft material. The imaging patterns we have detailed should be closely monitored using computed tomography angi-
ography surveillance to allow structural failures to be promptly identified and treated. (J Vasc Surg 2021;-:1-10.)
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d Type of Research: A multicenter, prospective, non-
randomized trial
d Key Findings: Eleven patients with a descending
thoracic aortic aneurysm from the Valiant EVO clin-
ical trial were identified with structural failure in their
thoracic stent grafts. Five patients had experienced
type IIIb endoleaks, with four having stent fractures
and loss of seam integrity, and six patients had stent
ring enlargements.
d Take Home Message: Late structural failures were
identified with the thoracic stent graft in the Valiant
Evo clinical trial. These can present as type IIIb endo-
leaks, stent fractures, and stent ring enlargement.
Lifelong surveillance using computed tomography
angiography is important to allow structural failures
to be promptly identified and appropriately treated.
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--- 2021NCT02652949).3 In response to these adverse events, the
manufacturer decided to issue a voluntary global recall
of the device in February 2021.
Stent graft failure modes can generally be grouped into
fractures of the metallic stent rings, suture breakage, and
other causes of fabric wear.4 Cyclical movement of the
metal stents due to the pulsatile environment can lead
to fatigue stress and fracture4,5; however, the occurrence
of stent fractures has been rare with modern grafts.6,7
The sutures in the graft can also fail by creating micro-
leakage where the suture penetrates the fabric,8 or a
broken suture can lead to detachment of a stent
ring9,10 or fabric disruption if the suture had joined two
edges of the fabric. Finally, fabric wear can occur from
excessive manipulation during implantation or balloon
dilation or the presence of calcification.11-13
Identifying structural failures of a graft is imperative
because failure can be associated with type IIIb endo-
leaks. Type IIIb endoleaks after thoracic endovascular
aortic repair (TEVAR) are rare but have been docu-
mented in a few case reports.14,15 Even with abdominal
endovascular aneurysm repair, both randomized control
trials and large multicenter registries of current genera-
tion stent grafts have reported rates <2%.11,16 Although
uncommon, type IIIb endoleaks are serious adverse
events because they result in blood flow back into the
aneurysm sac, resulting in a significant risk of rupture.16,17
When diagnosed, a type IIIb endoleak can generally be
successfully treated by relining the device.18,19 In the pre-
sent report, we have summarized the recurring patterns
in the imaging studies of patients with Navion stent graft
failure with the aim of increasing physician awareness in
the identification of possible failure modes, early recogni-
tion, and prompt treatment.
METHODS
Trial design and clinical and imaging follow-up
extension. The patients identified with type IIIb endo-
leaks and other imaging findings were a part of the
Valiant Evo U.S. and international clinical trials (Clinical-
Trials.gov identifiers, NCT02625324 and NCT02652949).
In brief, the trials were prospective, single-arm in-
vestigations of the Valiant Navion stent graft system for
the treatment of pathologies, including descending
thoracic aortic aneurysms (DTAAs) and penetrating
atherosclerotic ulcers. More details on the trial design
and the 30-day and 1-year outcomes have been previ-
ously reported.1,2 All the sites conducted the study in
accordance with the clinical investigation protocol and
received institutional review board or ethics committee
approval, as applicable. All the patients in the trials pro-
vided written informed consent, and the trials were
compliant with the Declaration of Helsinki (October
2013) and the laws and regulations of the countries in
which the clinical trials were conducted.The trials were originally designed with clinical and im-
aging follow-up, including independent core laboratory
analysis (Syntactx, New York, NY) through 1 year. A total
of 100 patients were enrolled between April 2016 and
March 2018. With the recent observations of type IIIb
endoleaks, the sponsor initiated an investigation in
which all sites were asked to submit their follow-up im-
aging studies beyond 1 year to the core laboratory for re-
view, including from patients who had withdrawn from
the study. The request for the retrospective imaging re-
view was made possible in the United States under a
Health Insurance Portability and Accountability Act
exception, given the urgency to assess patient safety,
and was communicated to the related institutional re-
view boards through the unanticipated adverse device
effects letter. For the sites outside the United States,
the unanticipated serious adverse device effects letter
sent to the ethics committees included language
regarding the core laboratory review of imaging studies
from all the study patients in the interest of patient safety
and specified how data privacy would be ensured for the
patients who had withdrawn from the trial.
Valiant Navion thoracic stent graft design and rele-
vance to imaging findings. The Valiant Navion stent graft
is constructed from a sheet of multifilament polyester
sewn into a cylindrical shape, resulting in a seam line
running along the length of the graft (Fig 1). The graft
also has a series of stent rings that are formed by joining
two ends of a stent ring with a cylindrical crimp sleeve.
The stent rings are formed at a larger diameter (w20%)
than that of the graft fabric diameter and sewn to the
outer surface of the graft fabric such that the crimp
sleeve on each stent ring is oriented w180 from the
seam line (Fig 1).
Fig 1. A, Construction of the Valiant Navion stent graft with the cross-section view showing the stent rings sewn
with the crimps located w180 from the graft seam. Also, a radiopaque side marker is nearly equidistant between
the seam and crimps (red circle). B, View of a graft with the seam running down the length of the graft (blue
arrows). C, View showing a line of crimps on the other side of the graft (green arrows).
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markers placed 120 from each other at the proximal
end of the fabric. One radiopaque side marker is sewn
between the third and fourth stent rings, with two radi-
opaque markers at the distal end of the fabric. Both the
side marker and the crimps can be identified using
high contrast-enhanced computed tomography (CT)
or radiography. Together, they can be used to deter-
mine the location of the seam because the side marker
is approximately equidistant between the crimps and
the seam.
Core laboratory image analysis. All core laboratory re-
views were performed on fully de-identified images.
The core laboratory assessed the images for evidence of
type IIIb endoleaks, stent ring fractures, and stent ring
enlargement, which were required to meet the following
criteria:
d Type IIIb endoleak: defined as blood flow through a
fabric disruption with confirmation with CT angiog-
raphy (CTA)
d Stent fracture: stents were considered fractured if a
visible gap was present in the ring, with be confirma-
tion by CT or radiography
d Stent ring enlargement: defined as an increase of the
diameter of a nitinol stent ring >1 mm of the nominal
graft diameter as measured by CT; the most conserva-
tive threshold was chosen to detect all possible events,
with the understanding that false-positive results could
also be identifiedRESULTS
Through 1 year, no structural failures or type IIIb endo-
leaks were detected.2 Of the 100 patients originally
enrolled, the core laboratory assessed the imaging
studies at $1 year for 83 patients, including some pa-
tients who had withdrawn from the clinical trials.
Through the retrospective core laboratory review, four
patients who had been treated for a DTAA were identi-
fied with late type IIIb endoleaks concomitant with stent
fracture and stent ring enlargement detected 36 to
49 months after the initial TEVAR implantation (Table I).
Two of the four patients were asymptomatic and had un-
dergone a complete relining procedure that successfully
excluded their endoleak. One of the four patients was
asymptomatic and the reintervention had been sched-
uled. Patient 1 underwent a relining procedure that suc-
cessfully excluded the type IIIb endoleak; however, the
patient died 4 days later. According to the investigator
review, the death was likely secondary to aortic rupture
at the level of the distal TEVAR extension, which had
been landed in a previously dissected aortic segment.
However, the cause of death could not be confirmed
because the family refused an autopsy.
Patient 5 did not have any stent fractures but experi-
enced a type IIIb endoleak that the core laboratory sus-
pected had resulted from fabric wear near a region of
calcification. The patient underwent a successful second-
ary procedure to treat the type IIIb endoleak but died
3 months later of noneaortic-related causes.
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5c F 74 Saccular 53 Type IIIb endoleak 34 85 Yes Reliningb
6c M 68 Fusiform 73 Ring enlargement 9 89 Yes NA
7 F 68 Saccular 63 Ring enlargement 24 47 No None
8 F 72 Fusiform 61 Ring enlargement 12 56 No None
9 M 76 Fusiform 64d Ring enlargement 39 58 No None
10c F 77 Fusiform 62 Ring enlargemente 53 56 No NA
11c M 84 Fusiform 66 Ring enlargement 47 72 Yes NA
F, Female; M, male; MAD, maximum aneurysm diameter; NA, not applicable; Pt. No., patient number.
aType IIIb endoleak, fracture, and/or ring enlargement.
bInformation on secondary procedures determined from site and/or investigator communication because the information was not entered in the
database.
cSubject withdrew from the study and did not provide consent for long-term follow-up in the trial; thus, data >1 year were either not available or
reported from site and/or investigator communication instead of the clinical study electronic case report form for these subjects.
dSubject 9 did not have 1-month imaging studies available; thus, we reported the preprocedure imaging measurement.
eOfficially reported by the core laboratory as ring deformation owing to an inability to locate the peaks to measure ring enlargement, although both
the core laboratory and the investigators reviewed imaging studies and believe the findings indicate ring enlargement.
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stent ring enlargement without any stent fracture or
type IIIb endoleak. The stent ring enlargements
measured by the core laboratory were all beyond the
margin of error that could have resulted from imaging
modality limitations or interobserver variability. Patient
6 underwent successful reintervention for type Ia and
Ib endoleaks within the first year,2 and the core labora-
tory reported no endoleaks after the secondary proced-
ure. However, patient 6 experienced had persistent
aneurysm expansion and died of unknown causes. The
other five patients have continued to be monitored
without reinterventions planned. None of the patients
treated for a penetrating atherosclerotic ulcer presented
with signs of structural failure of the graft at the last
follow-up examination.
Patient 1 (type IIIb endoleak, stent fractures along
seam line, stent ring enlargement). Patient 1 was a 66-
year-old man and had a saccular DTAA with a diameter
of 59 mm. The patient was treated with a Valiant Navion
stent graft (40 mm, 40 mm, 225 mm) successfullyadvanced and deployed in zone 4. The completion
angiography showed a type Ib and type II endoleak that
was resolved by balloon dilation. One day later, the pa-
tient presented with acute back pain. The CTA scan
revealed a focal aortic dissection at the distal end of the
graft that extended distally for 4.6 cm. The stent graft still
appeared to be positioned normally, without a sign of an
endoleak. Because the patient’s pain resolved without
further treatment, he was discharged 10 days after
procedure.
The patient was admitted 44 months after the index
procedure for acute left chest pain. CTA showed a type
IIIb endoleak (Fig 2, A) and an aneurysm sac increase of
>1 cm. Angiography confirmed blood flow outside of
what should have been the cylindrical stent graft bound-
ary (Fig 2, B). A secondary procedure was performed to
reline the graft, and the type IIIb endoleak was success-
fully excluded with no evidence of any endoleaks. Four
days after the secondary procedure, the patient was
found unresponsive after an episode of left flank pain
and pronounced dead, with the family refusing an au-
topsy. A retrospective review of the imaging studies
Fig 2. Patient 1. A, Computed tomography angiography (CTA) at 44 months after treatment showing contrast
outside the stent graft profile (blue arrow) indicative of a type IIIb endoleak. B, Angiogram showing the side
marker (red circle) identified and crimps evident along the inner curvature (green arrows). These findings indicate
the graft seam is on the outer curvature and coincident with the location of the fractured stents (blue arrows).
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placement of the distal TEVAR extension device in a pre-
viously dissected and fragile portion of the aorta
(Supplementary Fig 1, online only).
From the combination of CTA scans and angiography, it
was evident that the stent graft fractures coincided with
the location of the seam line of the graft. On the angio-
gram (Fig 2, B), the side marker was identified in the mid-
dle of the aorta, with the crimps visible along the inner
curvature. This confirmed that the seam line was on
the outer curvature where the stents had fractured. The
three-dimensional CTA reconstructions (Fig 3), per-
formed between 24 and 41 months after the index pro-
cedure, showed that four stent rings had fractured,
with an additional stent ring fracture that occurred be-
tween 41 and 44 months. Stent ring enlargement had
occurred as early as 24 months after initial treatment.
Patient 3 (type IIIb endoleak, stent fractures along
seam line, stent ring enlargement). The details and im-
ages from patient 3 are shown in Supplementary Fig 2
(online only).
Patient 4 (type IIIb endoleak, distal stent fractures
along seam line, stent ring enlargement). Patient 4 was
a 74-year-old woman with a fusiform DTAA with a
diameter of 56 mm. The patient was implanted with two
Valiant Navion stent grafts (proximal device, 34 mm,
34 mm, 225 mm; distal device, 43 mm, 43 mm, 175 mm)
with a zone 3 proximal landing. The patient tolerated the
procedure well and was discharged in 2 days. The CTAimaging studies at 1 and 12 months showed that the
distance between the distal end of the graft and the
distal edge of the celiac artery had increased by 17 mm
(from 19 mm to 36 mm; Fig 4, A and B). The core labo-
ratory did not consider this a distal migration owing to
the corresponding increase in the centerline length of
the thoracic aorta.
At 49 months, the patient had new findings of pulmo-
nary malignancy and was referred for further evaluation.
In the 49-month imaging study (Fig 4, C), stent rings 9, 10,
and 11 of the distal graft were found to have fractured,
coincident with the location of the graft seam line. The
findings was further confirmed by the 51-month chest
radiograph (Fig 4, D). Because the patient elected to un-
dergo partial pneumonectomy and adjuvant therapy,
reintervention for the stent fractures and type IIIb endo-
leak was deferred. At the last follow-up visit, the patient
was scheduled for additional imaging studies and a
planned endovascular reintervention.
Patient 11 (single stent ring enlargement). Patient 11
was an 84-year-old man with a fusiform DTAA with a
diameter of 60 mm. The patient had two Valiant Navion
stent grafts placed with the proximal device (43 mm,
43 mm, 225 mm) landed in zone 3 and the distal device
(46 mm, 46 mm, 175 mm) in zone 4. The patient tolerated
the procedure well and was discharged in 2 days. Be-
tween 12 and 48 months, stent ring enlargement was
suspected because, although the flow was contained
within the boundary of the stent fabric, a focal stent ring
detachment from the fabric on the upper edge was
Fig 3. Patient 1. Three-dimensional computed tomogra-
phy angiography (CTA) reconstructions over time with the
stent rings numbered starting from the proximal end of
the graft and showing no stent fractures at 24 months. At
41 months, four stent fractures (red numbers) were found,
coincident with the seam line, with an additional stent
fracturing by 44 months. The individual stent ring di-
ameters over time showed ring enlargement (yellow
numbers) as early as 24 months.
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detected endoleaks, and further monitoring was
planned.
DISCUSSION
Type IIIb endoleaks are serious adverse events owing to
repressurization of the aneurysm sac, which puts pa-
tients at an increased risk of rupture.16 In the literature,
the incidence of type IIIb endoleaks has been reported
to be <2%.11,16 At the time of the present analysis of the
Valiant Evo clinical trial, five patients had been identified
with late type IIIb endoleaks. Four of these patients had
stent fractures coincident with the seam and the fifth
endoleak was attributed to calcium erosion. The observa-
tions of stent fractures and type IIIb endoleaks led the
manufacturer to initiate a voluntary global recall of the
Navion devices in the interest of patient safety.
Althoug type IIIb endoleaks require immediate atten-
tion, the existing data have shown that type IIIb endo-
leaks can often be successfully treated
endovascularly.20-22 At the time of our report, four pa-
tients had undergone a relining procedure, and all rein-
terventions had successfully sealed the type IIIbendoleak. However, for patient 1, the distal end of the
relining graft might have induced aortic rupture,
because the distal landing was in a previously dissected
and fragile aortic segment (Supplementary Fig 1, online
only).
The multiple stent fractures in line with the seam was a
different pattern from the typical description of stent
ring fractures from case reports of other grafts.4,10,23
From this image analysis, one could hypothesize that
the finding of stent fractures along the same longitudinal
line as the seam, opposite the stent crimps, is highly sus-
picious for the loss of integrity of the seam. A significant
loss of seam integrity might allow for unanticipated
loading and/or displacement of the stent rings, which
might, in turn, result in an increased risk of stent ring frac-
ture. Although previous reports have also concluded that
excessive mechanical stress can make stent rings more
prone to failure,23,24 this does not explain the cause of
the loss of seam integrity, which is still under
investigation.
Stent ring enlargement was also identified as a failure
mode in our retrospective analysis and believed to result
from detachment of the stent from the surface of the
graft material. Although it is not common practice to
measure stent ring enlargement, we would emphasize
the importance of assessing the stent ring sizes along
the length of the graft from the cross-sectional CT im-
ages (Fig 5). The detachment of stent rings from grafts af-
ter suture breakage has been previously reported with
other grafts,9,10,20 and the additional movement of a de-
tached ring could result in stent fracture.23,24 Although
no cause has been identified for stent ring enlargement,
one possibility is the loss of suture fixation integrity.
Because suture failure could lead to the development
of endoleaks,10 compliance with follow-up imaging
recommended.
We would emphasize that the root cause analysis of the
structural failures is still ongoing, and the results will be
reported when available. A number of engineering
design factors can contribute to structural failure,
including the design, material, construction, and use of
the component. Several different design elements, mate-
rials, and manufacturing methods are unique to the
Valiant Navion device compared with those used in pre-
vious generations of devices such as the Valiant Captivia
(Medtronic Inc). No cases of stent fracture or type IIIb
endoleak were reported through 5 years in the VALOR
II (the Valiant thoracic stent graft system clinical study),21
Dissection,22 and RESCUE (study to determine if the
Valiant stent graft is safe and effective in treating patients
who have a blunt thoracic aortic injury)25 clinical trials
with the Valiant Captivia device.
Strict adherence to lifelong surveillance with a mini-
mum of annual CTA is important for the timely identifi-
cation of any structural failure of stent grafts.26 If a
patient presents with a line of stent fractures, further
Fig 4. Patient 4. A,B, Three-dimensional computed tomography angiography (CTA) reconstruction showing the
distance between the distal edge of the graft and distal edge of the celiac artery had increased by 17 mm by the
12-month imaging follow-up. The bottom three stent rings had fractured by the 49-month CTA study (C), and the
fractured stents were also clear on the 51-month chest radiography (D).
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Strict imaging follow-up with CTA should be suggested
for patients found with a single stent fracture without
endoleaks and for patients identified with single stent
ring enlargement. In accordance with the Society for
Vascular Surgery guidelines,27,28 lifelong surveillance is
warranted because a single stent fracture and suture
breakage can lead to fabric degradation over time.8,9
Finally, a retrospective review of previous imaging studies
might be beneficial because the patterns of graft failure
we have described are difficult to assess and could be
overlooked initially.
To detect these late graft structural failures (Table II), we
would recommend high quality CTA imaging studies,
and, ideally, the stent diameter should be sized in planes
orthogonal to the graft’s main longitudinal axis to assess
for stent ring enlargement. Using these same images, the
outside of the stent graft boundaries should be carefully
examined for any presence of contrast. Moreover, three-
dimensional reconstructions with the centerline should
be obtained from CTA scans to identify stent
breakage.5,23 These can also be found by carefulevaluation of plain radiographs of the graft,31,32 although
overlapping stents can sometimes render the fractures
difficult to ascertain. Although digital subtraction angi-
ography is the most accurate method to differentiate
the types of endoleaks, it is generally not used because
it is invasive.33-35
The guidelines at present recommend treatment for
type I and III endoleaks or type II endoleaks with aneu-
rysm expansion.26,29,30 If an endovascular aortic reinter-
vention is planned for any disease progression in a
patient previously implanted with a Valiant Navion stent
graft, we would suggest relining the previously treated
areas, even without the diagnosis of other failures. In
contrast to the reported data in which type IIIb endo-
leaks are often treated with spot relining using cuffs or
limb extensions to exclude the endoleak,11,36 we would
suggest complete relining of the graft similar to the
method used by Lemmon et al37 to avoid future poten-
tial complications.
Finally, the distal seal has generally been discussed in
the context of type Ib endoleaks.2,38,39 However, reported
studies have also suggested the loss of fixation and
Fig 5. Patient 11. Computed tomography angiography (CTA) showing stent ring enlargement that occurred be-
tween 12 and 48 months. The stent appears to have detached from the fabric, although this did not lead to a type
IIIb endoleak. The nominal stent graft diameter was 43 mm; the seam location is marked by blue arrows.
Table II. Imaging recommendations for evaluation of stent graft structural failures
Complication to look for Findings indicative of complication
Type IIIb endoleak Retrospective review of previous imaging studies
Lifelong surveillance with a minimum of annual high quality CTA imaging studies
Further interrogation of any presence of contrast outside stent graft boundaries or irregular, noncircular
lumen margins, which might indicate fabric defects in accordance with society guidelines26,29,30
Failure of stent rings or
fabric seam
Retrospective review of previous imaging studies
Lifelong surveillance with a minimum of annual high quality CTA imaging studies
Sizing of stent diameters in planes orthogonal to the graft main longitudinal axis to assess for ring
enlargement
Careful evaluation of three-dimensional reconstructions or plain radiographs to identify stent fractures
Identification of seam line using CT scans of visible crimps and radiopaque markers
CT, Computed tomography; CTA, computed tomography angiography.
8 Verzini et al Journal of Vascular Surgery
--- 2021migration will result in increased movement of the graft
and fatigue stress on the stent rings.5,23 Aortic elongation
will bemore pronounced at the distal end of the thoracic
aorta,40,41 and the morphologic changes in the anatomy
will affect the structural integrity of grafts.2,4 Further-
more, angulation is a well-discussed risk factor for graft
migration and a compromised seal.42,43 All these factors
could have played a role in the structural failures seen in
our patient 4. Consistent with the present guidelines,
which recommend endovascular treatment of all type
III endoleaks,26,29,30 we believe it is imperative to have a
good seal zones to minimize the risk of further
complications.
Study limitations. One limitation of the present retro-
spective analysis was that the original trial protocol
was concluded at 1 year. Thus, clinical information on
secondary procedures and mortality was not available
for patients who had withdrawn from the study despite
the core laboratory assessing the images from 83 pa-
tients. Also, if the CT images are not orthogonal to the
main axis of the graft, a margin of error will beintroduced into the calculation of the stent ring diam-
eter. The 1-mm threshold beyond the nominal graft
diameter as the definition for stent ring enlargement
was conservatively chosen to identify all possible events,
with the understanding that potential false-positive re-
sults would be found. Although a 1-mm threshold might
be too strict a criterion to apply in the clinical setting
because of imaging modality limitations or interob-
server variability, stent ring enlargement resulting from
detachment from the graft material can be expected to
be >1 mm owing to the oversizing of the stent rings
relative to the stent fabric. Likewise, without explanted
devices to examine, the structural graft failures identi-
fied using the various imaging techniques could not be
fully confirmed.
CONCLUSIONS
In the present preliminary analysis, several late struc-
tural graft failures occurred in the Valiant Evo U.S. and in-
ternational clinical trials. We have described the imaging
patterns associated with the type IIIb endoleaks, stent
fractures, and stent ring enlargements seen in the
Journal of Vascular Surgery Verzini et al 9
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seam integrity or detachment of the stent rings from
the surface of the graft fabric. In accordance with society
guidelines,26-28 lifelong surveillance for these imaging
trends should be performed with CTA to allow structural
failures to be promptly identified and treated. The com-
plete understanding of the mechanisms of failure re-
quires further investigation, which is underway.
The authors acknowledge the following persons from
Medtronic Inc: Alessandro Marucchini, Brian Glynn, and
Polina Rapoport for clinical and engineering expertise
and Victoria Rendon and Ming-Jay Chow for their help
in the preparation of our report.
AUTHOR CONTRIBUTIONS
Conception and design: FV, EC, AK, YS, RH, KO, SR, AA
Analysis and interpretation: FV, KO, SR, AA
Data collection: FV, EC, AK, YS, RH, KO, SR, AA
Writing the article: FV, KO, AA
Critical revision of the article: FV, EC, AK, YS, RH, KO, SR,
AA
Final approval of the article: FV, EC, AK, YS, RH, KO, SR, AA
Statistical analysis: Not applicable
Obtained funding: Not applicable
Overall responsibility: FV
REFERENCES
1. Azizzadeh A, Desai N, Arko FR III, Panneton JM, Thaveau F, Hayes P,
et al. Pivotal results for the Valiant Navion stent graft system in the
Valiant Evo global clinical trial. J Vasc Surg 2019;70:1399-408.e1.
2. Verzini F, Desai N, Arko FR III, Panneton JM, Thaveau F, Dagenais F,
et al. Clinical trial outcomes and thoracic aorta morphometry after
one year with the Valiant Navion stent graft system [e-pub ahead of
print]. J Vasc Surg, https://doi.org/10.1016/j.jvs.2021.01.047. Accessed
February 13, 2021.
3. Chaikof EL, Blankensteijn JD, Harris PL, White GH, Zarins CK,
Bernhard VM, et al. Reporting standards for endovascular aortic
aneurysm repair. J Vasc Surg 2002;35:1048-60.
4. Jacobs TS, Won J, Gravereaux EC, Faries PL, Morrissey N,
Teodorescu VJ, et al. Mechanical failure of prosthetic human im-
plants: a 10-year experience with aortic stent graft devices. J Vasc
Surg 2003;37:16-26.
5. Ueda T, Takaoka H, Petrovitch I, Rubin GD. Detection of broken su-
tures and metal-ring fractures in AneuRx stent-grafts by using three-
dimensional CT angiography after endovascular abdominal aortic
aneurysm repair: association with late endoleak development and
device migration. Radiology 2014;272:275-83.
6. Riambau V, Giudice R, Trabattoni P, Llagostera S, Fadda G, Lenti M,
et al. Prospective multicenter study of the low-profile relay stent-
graft in patients with thoracic aortic disease: the Regeneration
study. Ann Vasc Surg 2019;58:180-9.
7. Torsello GF, Inchingolo M, Austermann M, Torsello GB, Panuccio G,
Bisdas T. Durability of a low-profile stent graft for thoracic endovas-
cular aneurysm repair. J Vasc Surg 2017;66:1638-43.
8. Bussmann A, Heim F, Delay C, Girsowicz E, Del Tatto B, Dion D, et al.
Textile aging characterization on new generations of explanted
commercial endoprostheses: a preliminary study. Eur J Vasc Endo-
vasc Surg 2017;54:378-86.
9. Jones SM, Vallabhaneni SR, McWilliams RG, Naik J, Nicholas T,
Fisher RK. Type IIIb endoleak is an important cause of failure
following endovascular aneurysm repair. J Endovasc Ther 2014;21:
723-7.
10. Wanhainen A, Nyman R, Eriksson MO, Björck M. First report of a late
type III endoleak from fabric tears of a Zenith stent graft. J Vasc Surg
2008;48:723-6.11. Maleux G, Poorteman L, Laenen A, Saint-Lèbes B, Houthoofd S,
Fourneau I, et al. Incidence, etiology, and management of type III
endoleak after endovascular aortic repair. J Vasc Surg 2017;66:
1056-64.
12. Dayama A, Tsilimparis N, Kasirajan K, Reeves JG. Late Gore
Excluder endoprosthesis fabric tear leading to abdominal aortic
aneurysm rupture 5 years after initial implant. J Vasc Surg
2013;57:221-4.
13. Kwon J, Dimuzio P, Salvatore D, Abai B. Incidence of stent graft
failure from type IIIB endoleak in contemporary endovascular
abdominal aortic aneurysm repair. J Vasc Surg 2020;71:645-53.
14. Uehara K, Inoue T, Matsuo J, Sasaki H, Matsuda H. Type IIIb endoleak
from stent suture lines of a thoracic endograft. J Vasc Surg Cases
Innov Tech 2019;5:214-7.
15. Müller-Eschner M, Peters AS, Meisenbacher K, Böckler D, Bischoff MS.
Type IIIb endoleak after thoracic endovascular aortic repair caused
by endoanchor dislocation. Ann Vasc Surg 2015;29. 1019.e7-1019.e10.
16. Fujimura N, Ichihashi S, Matsubara K, Shibutani S, Harada H, Obara H,
et al. Type IIIb endoleak is not extremely rare and may be under-
diagnosed after endovascular aneurysm repair. J Vasc Interv Radiol
2019;30:1393-9.e1.
17. Harris PL, Vallabhaneni SR, Desgranges P, Becquemin JP, van
Marrewijk C, Laheij RJ. Incidence and risk factors of late rupture,
conversion, and death after endovascular repair of infrarenal aortic
aneurysms: the EUROSTAR experience. European Collaborators on
Stent/graft techniques for aortic aneurysm repair. J Vasc Surg
2000;32:739-49.
18. Bucci F, Fiengo L, Valerio N, Ferdani M. Late type IIIb endoleak after
endovascular aneurysm repair: case report and review of the litera-
ture. G Chir 2011;32:329-33.
19. Shao J, Zhang X, Chen Y, Zheng Y, Liu B. Endovascular repair of late
type IIIb endoleak after endovascular aneurysm repair: a case report.
BMC Cardiovasc Disord 2019;19:183.
20. Leopardi M, Salerno A, Scarpelli P, Ventura M. Type III B endoleak
leading to aortic rupture after endovascular repair: analysis of errors
in follow up and treatment. CVIR Endovasc 2018;1:9.
21. Conrad MF, Tuchek J, Freezor R, Bavaria J, White R, Fairman R. Re-
sults of the VALOR II trial of the Medtronic Valiant thoracic stent
graft. J Vasc Surg 2017;66:335-42.
22. Bavaria JE, Brinkman WT, Hughes GC, Shah AS, Charlton-Ouw KM,
Azizzadeh A, et al. Five-year outcomes of endovascular repair of
complicated acute type B aortic dissections [e-pub ahead of print]. J
Thorac Cardiovasc Surg, https://doi.org/10.1016/j.jtcvs.2020.03.162.
Accessed May 13, 2020.
23. Roos JE, Hellinger JC, Hallet R, Fleischmann D, Zarins CK, Rubin GD.
Detection of endograft fractures with multidetector row computed
tomography. J Vasc Surg 2005;42:1002-6.
24. Bashir MR, Ferral H, Jacobs C, McCarthy W, Goldin M. Endoleaks after
endovascular abdominal aortic aneurysm repair: management
strategies according to CT findings. AJR Am J Roentgenol 2009;192:
W178-86.
25. Patel HJ, Azizzadeh A, Matsumoto AH, Velazquez OC, Rovin JD,
Lombardi JV, et al. Five-year outcomes from the United States pivotal
trial of Valiant Captivia stent graft for blunt aortic injury. Ann Thorac
Surg 2020;110:815-20.
26. Chaikof EL, Dalman RL, Eskandari MK, Jackson BM, Lee WA,
Mansour MA, et al. The Society for Vascular Surgery practice guide-
lines on the care of patients with an abdominal aortic aneurysm.
J Vasc Surg 2018;67:2-77.e2.
27. Upchurch GR Jr, Escobar GA, Azizzadeh A, Beck AW, Conrad MF,
Matsumura JS, et al. Society for Vascular Surgery clinical practice
guidelines of thoracic endovascular aortic repair for descending
thoracic aortic aneurysms. J Vasc Surg 2021;73:55s-83s.
28. Czerny M, Schmidli J, Adler S, van den Berg JC, Bertoglio L, Carrel T,
et al. Current options and recommendations for the treatment of
thoracic aortic pathologies involving the aortic arch: an expert
consensus document of the European Association for Cardio-
Thoracic surgery (EACTS) and the European Society for Vascular
Surgery (ESVS). Eur J Cardiothorac Surg 2018;55:133-62.
29. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD,
Eggebrecht H, et al. 2014 ESC guidelines on the diagnosis and
treatment of aortic diseases: document covering acute and
chronic aortic diseases of the thoracic and abdominal aorta of
the adult. The Task Force for the Diagnosis and Treatment of
10 Verzini et al Journal of Vascular Surgery
--- 2021Aortic Diseases of the European Society of Cardiology (ESC). Eur
Heart J 2014;35:2873-926.
30. Wanhainen A, Verzini F, Van Herzeele I, Allaire E, Bown M,
Cohnert T, et al. Editor’s choice e European Society for Vascular
Surgery (ESVS) 2019 clinical practice guidelines on the manage-
ment of abdominal aorto-iliac artery aneurysms. Eur J Vasc Endo-
vasc Surg 2019;57:8-93.
31. Falkenberg M, Cronqvist J, Malina M. Early stent fracture and collapse
of a Zenith TX2 thoracic stent graft used for traumatic aortic rupture.
Vascular 2011;19:287-90.
32. Stefaniak K, Stanisic M, Gabriel M, Oszkinis G. Diagnostic imaging
methods applied in long-term surveillance after EVAR: will
computed tomography angiography be replaced by other
methods? Postepy Kardiol Interwencyjnej 2016;12:6-12.
33. Pini R, Faggioli G, Mascoli C, Freyrie A, Gargiulo M, Stella A. The
diagnostic and treatment challenge of type IIIb endoleaks. J Vasc
Surg Cases 2015;1:249-53.
34. Tsoumakidou G, Brountzos E. Detection of complications after aortic
stent grafting. Eur Cardiol 2010;6:83-7.
35. Stavropoulos SW, Charagundla SR. Imaging techniques for detec-
tion and management of endoleaks after endovascular aortic
aneurysm repair. Radiology 2007;243:641.
36. Lee WA, Huber TS, Seeger JM. Late type III endoleak from graft
erosion of an Excluder stent graft: a case report. J Vasc Surg 2006;44:
183-5.
37. Lemmon G, Barleben A, Nelson P, Garrett HE Jr. Diagnosis and
relining techniques for delayed type IIIB endoleaks with the second-
generation AFX endograft. J Vasc Surg Cases Innov Tech 2019;5:51-3.38. Berezowski M, Morlock J, Beyersdorf F, Jasinski M, Plonek T, Siepe M,
et al. Inaccurate aortic stent graft deployment in the distal landing
zone: incidence, reasons and consequences. Eur J Cardiothorac Surg
2018;53:1158-64.
39. Geisbüsch P, Skrypnik D, Ante M, Trojan M, Bruckner T, Rengier F,
et al. Endograft migration after thoracic endovascular aortic repair.
J Vasc Surg 2019;69:1387-94.
40. Alberta HB, Takayama T, Panthofer A, Cambria RP, Farber MA,
Jordan WD, et al. Thoracic endovascular aortic repair migration and
aortic elongation differentiated using dual reference point analysis.
J Vasc Surg 2018;67:382-8.
41. Chen C-K, Chou H-P, Chang Y-Y, Shih C-C. Elongation of the aorta
after thoracic endovascular aortic repair: a longitudinal study. Int J
Environ Res Public Health 2020;17:1205.
42. Mathlouthi A, Locham S, Dakour-Aridi H, Black JH, Malas MB. Impact
of suprarenal neck angulation on endovascular aneurysm repair
outcomes. J Vasc Surg 2020;71:1900-6.
43. Jasinski PT, Adrahtas D, Monastiriotis S, Tassiopoulos AK. Early and
late endograft limb proximal migration with resulting type 1b
endoleak following an EVAR for ruptured AAA. Case Rep Vasc Med
2017;2017:4931282.Submitted Mar 23, 2021; accepted Apr 13, 2021.
Additional material for this article may be found online
at www.jvascsurg.org.
Supplementary Fig 1 (online only). Patient 1. Additional details surrounding the rupture at the level of the distal
thoracic endovascular aortic repair (TEVAR) extension. A, One day after the initial TEVAR procedure, the patient
complained of acute back pain. The three-dimensional reconstruction and cross-sectional computed tomogra-
phy (CT) images confirmed a focal aortic dissection at the distal end of the graft, which extended distally for
4.6 cm. The stent graft still appeared to be positioned normally without signs of an endoleak. Because the pa-
tient’s pain had resolved without further treatment, the patient was discharged home 10 days after procedure. B,
Imaging study performed at 44 months after index procedure and before the relining procedure showing false
lumen (FL) of the previously dissected section of the aorta appeared to have thrombosed and the true lumen (TL)
volume had increased. C, A secondary procedure was performed to reline the graft, and the type IIIb was suc-
cessfully excluded with no evidence of endoleaks. Completion angiogram showing the distal end of the relining
graft landed at the level of the previously dissected and fragile aorta. Four days after the secondary procedure, the
patient was found unresponsive after an episode of left flank pain and pronounced dead of suspected aortic
rupture at the level of the distal TEVAR extension.
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Supplementary Fig 2 (online only). Patient 3 (type IIIb endoleak, stent fractures along seam line, and stent ring
enlargement). The patient was a 65-year-old woman with a fusiform descending thoracic aortic aneurysm (DTAA)
with diameter of 62 mm. The patient underwent implantation with a single Valiant Navion stent graft (37 mm,
37 mm, 225 mm) and a zone 3 proximal landing. On the 24-month imaging study, no endoleaks, stent fractures, or
aneurysm enlargement was observed. However, the diameters of stent rings 4, 5, 6, and 7 had enlarged. A, Be-
tween the 24- and 36-month imaging studies, stent rings 5, 6, 7, and 8 had fractured, and stent rings 4 and 9
showed stent ring enlargement. B, The seam of the graft was identified at the inner curvature, and the fractures
were in line with the graft seam shown on the cross-section computed tomography (CT) scan. At last follow-up,
the patient was scheduled for an endovascular reintervention.
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